Mylan Pharmaceuticals ULC Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Mylan Pharmaceuticals ULC Pharmaceutical Import Records from India — 8 Products, $6.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Pharmaceuticals ULC — Pharmaceutical Importer Profile (2026) | 8 Products, $6.3M Trade | TransData Nexus

Mylan Pharmaceuticals ULC

Pharmaceutical Importer · Canada · Gastrointestinal Focus · $6.3M Total Trade · DGFT Verified

Mylan Pharmaceuticals ULC is a pharmaceutical importer based in Canada with a total trade value of $6.3M across 8 products in 5 therapeutic categories. Based on 125 verified import shipments from Indian Customs (DGFT) records, Mylan Pharmaceuticals ULC is the #1 buyer in 1 product including Naproxen. Mylan Pharmaceuticals ULC sources from 3 verified Indian suppliers, with Mylan Laboratories Limited accounting for 95.1% of imports.

Mylan Pharmaceuticals ULC — Import Portfolio & Supplier Network

Mylan Pharmaceuticals ULC import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Pharmaceuticals ULC?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$17.4M	577	95.1%
Cipla Limited	$700.0K	53	3.8%
Natco Pharma Limited	$200.0K

What Formulations Does Mylan Pharmaceuticals ULC Import?

Formulation	Value	Ships
Sanis pantoprazole t 40 MG 100 bt TAB	$350.0K	7
Mylan naproxen / esomeprazole mr 500 MG	$300.0K	6
Mylan pantoprazole t 40 MG TAB 100 bt	$200.0K	4
Dymista (azelastine hcl	$200.0K	4
Mylan-naproxen/esomeprazole mr	$200.0K	4
Myl esomeprazole 40 MG 100 bt TAB	$150.0K	3
Sanis-pantoprazole t 40 MG 100bt TAB	$150.0K	3
Harmless medicines mylan-lansoprazole	$150.0K	3
Pantoprazole t 40 MG 100bt TAB packs : 100's bottle 52,816.000	$150.0K	3
Mylan naproxen esomeprazole mr 500MG 20MG TAB 60bt packs	$150.0K	3
Pantoprazole t 40MG TAB 100bt TAB	$150.0K	3
Pantoprazole mag TAB gr 40MG 100bt ca mypacks	$150.0K	3
Esom napr TAB pr 20 500MG 60bt ca my packs	$150.0K	3
Pantoprazol mag TAB gr 40MG 100bt ca sanpacks	$150.0K	3
Harmless medicines, esom/napr TAB pr 20/500MG 60bt ca my (34539 packs)	$150.0K	3

Mylan Pharmaceuticals ULC imports 441 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pantoprazole	Gastrointestinal	$4.0M	81	0.1%	3
2	Esomeprazole	Gastrointestinal	$600.0K	12	0.1%	5
3	Acyclovir	Antivirals	$500.0K	10	0.4%	3
4	Naproxen	Analgesics & Antipyretics	$350.0K	7	0.3%	1
5	Omeprazole	Gastrointestinal	$350.0K	7	0.1%	6
6	Valacyclovir	Antivirals	$200.0K	4	0.2%	9
7	Gliclazide	Advanced Diabetes Medications	$100.0K	2	0.0%	4
8	Proguanil	Antimalarial & Antiparasitic	$100.0K	2	0.0%	8

Mylan Pharmaceuticals ULC imports 8 pharmaceutical products across 5 categories into Canada totaling $6.3M. The company is the #1 buyer for 1 product: Naproxen.

Mylan Pharmaceuticals ULC — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Pharmaceuticals ULC is a Canadian pharmaceutical company specializing in the importation and distribution of finished pharmaceutical formulations. Established in 2009, it operates as a subsidiary of Mylan N.V., a global leader in generic and specialty pharmaceuticals. The company's headquarters are located at 85 Advance Road, Etobicoke, Ontario, M8Z 2S6, Canada. (dhpp.hpfb-dgpsa.ca)

Mylan Pharmaceuticals ULC plays a significant role in Canada's pharmaceutical distribution network by providing a diverse range of generic medications. Its portfolio includes products across various therapeutic categories, ensuring access to affordable healthcare solutions for Canadian patients. The company's operations encompass business development, sales and marketing, regulatory affairs, and packaging, reflecting its comprehensive approach to pharmaceutical distribution.

2Distribution Network

Mylan Pharmaceuticals ULC's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Canada. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are robust, supporting nationwide coverage. This infrastructure enables timely and reliable distribution of medications to various healthcare providers, including hospitals, pharmacies, and clinics. The company's operations are centralized at its Etobicoke facility, which serves as the hub for its distribution activities. (dhpp.hpfb-dgpsa.ca)

3Industry Role

In Canada's pharmaceutical supply chain, Mylan Pharmaceuticals ULC functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company enhances the availability of generic medications in the Canadian market. This role is crucial in providing cost-effective alternatives to brand-name drugs, thereby contributing to the sustainability of Canada's healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Pharmaceuticals ULC

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Pharmaceuticals ULC demonstrates a high degree of sourcing concentration, with 95.1% of its imports from India supplied by Mylan Laboratories Limited. This significant dependency on a single supplier indicates a strategic choice to leverage Mylan Laboratories' extensive product portfolio and established manufacturing capabilities. However, such concentration also presents potential risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges within the supplier's facilities. The stability of this relationship is evidenced by the consistent volume of shipments over the years, suggesting a strong and reliable partnership.

2Supply Chain Resilience

The resilience of Mylan Pharmaceuticals ULC's Indian supply chain is bolstered by its diversified supplier base, comprising three unique suppliers. This diversification mitigates risks associated with over-reliance on a single source. The company's importation of 441 unique formulations further indicates a broad product range, reducing the impact of potential supply disruptions. While specific details about backup suppliers and shipping routes are not publicly available, the company's established relationships with reputable Indian manufacturers suggest a commitment to maintaining supply chain continuity. Additionally, the adherence of these suppliers to international quality standards, such as WHO GMP, enhances the overall reliability and compliance of the supply chain.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the primary regulatory authority overseeing pharmaceutical imports is Health Canada, which ensures that all imported drugs meet the country's safety, efficacy, and quality standards. The Food and Drugs Act and its associated regulations govern the importation, distribution, and sale of pharmaceutical products in Canada. For Indian generics to be marketed in Canada, they must undergo a rigorous evaluation process, including submission of a New Drug Submission (NDS) to Health Canada, demonstrating bioequivalence to the reference product. This process ensures that imported generics are therapeutically equivalent to their brand-name counterparts, providing Canadian patients with safe and effective treatment options.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Canada are stringent. Companies like Mylan Pharmaceuticals ULC must obtain an Establishment License from Health Canada, authorizing them to import and distribute drugs. Additionally, imported pharmaceutical products must be manufactured in facilities that comply with Good Manufacturing Practices (GMP). Health Canada recognizes GMP certifications from reputable international bodies, including the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition facilitates the importation of high-quality generics from countries like India, provided they meet these international standards.

Mylan Pharmaceuticals ULC — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Pharmaceuticals ULC's focus on importing products in the gastrointestinal, antiviral, and analgesic therapeutic categories aligns with prevalent health concerns in Canada. The high import values of drugs like Pantoprazole and Esomeprazole indicate a significant demand for gastrointestinal treatments. Similarly, the inclusion of antivirals and analgesics reflects the company's strategy to address common conditions such as infections and pain management. This targeted approach ensures that Mylan Pharmaceuticals ULC's product offerings meet the therapeutic needs of the Canadian population.

2Sourcing Profile

Mylan Pharmaceuticals ULC's sourcing strategy emphasizes the importation of generic drugs from India, leveraging the country's robust pharmaceutical manufacturing sector. The company's preference for finished pharmaceutical formulations over raw active pharmaceutical ingredients (APIs) allows for a more streamlined supply chain and ensures that products are ready for distribution upon arrival. India's compliance with international GMP standards and its competitive pricing further enhance its appeal as a sourcing destination for Mylan Pharmaceuticals ULC.

3Market Positioning

Seller's Guide — How to Become a Supplier to Mylan Pharmaceuticals ULC

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Mylan Pharmaceuticals ULC. The company's diversified sourcing strategy, encompassing multiple suppliers and a wide range of formulations, indicates a willingness to expand its supplier base. Indian exporters can explore this opportunity by ensuring compliance with Health Canada's regulatory requirements and demonstrating the quality and reliability of their products. By aligning with Mylan Pharmaceuticals ULC's sourcing needs, Indian suppliers can enhance their presence in the Canadian market and contribute to the availability of affordable healthcare solutions.

2Requirements & Qualifications

Indian exporters seeking to supply Mylan Pharmaceuticals ULC must ensure that their manufacturing facilities comply with international GMP standards recognized by Health Canada, such as EU GMP, WHO GMP, or PIC/S. Products must undergo bioequivalence studies to demonstrate therapeutic equivalence to the reference product. Additionally, exporters must adhere to Health Canada's labeling requirements, including bilingual labeling in English and French, and ensure that products meet all quality and safety standards mandated by Canadian regulations.

How to Approach

Frequently Asked Questions — Mylan Pharmaceuticals ULC

What products does Mylan Pharmaceuticals ULC import from India?

Mylan Pharmaceuticals ULC imports 8 pharmaceutical products across 5 categories. Top imports: Pantoprazole ($4.0M), Esomeprazole ($600.0K), Acyclovir ($500.0K), Naproxen ($350.0K), Omeprazole ($350.0K).

Who supplies pharmaceuticals to Mylan Pharmaceuticals ULC from India?

Mylan Pharmaceuticals ULC sources from 3 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (95.1% of imports, $17.4M).

What is Mylan Pharmaceuticals ULC's total pharmaceutical import value?

Mylan Pharmaceuticals ULC's total pharmaceutical import value from India is $6.3M, based on 125 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Pharmaceuticals ULC focus on?

Mylan Pharmaceuticals ULC imports across 5 categories. The largest: Gastrointestinal (80.0%), Antivirals (11.2%), Analgesics & Antipyretics (5.6%).

Get Full Mylan Pharmaceuticals ULC Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.